Kevin Van Geem, MS

Kevin Van Geem received his MS in Bioethics from Columbia University in 2016, after completing the pre-medical science post-baccalaureate certificate program. Mr. Van Geem was a research coordinator in the pediatric emergency department from 2013-2014, working on a variety of studies ranging from Asthma registries to Traumatic Brain Injury, and teen attitudes on contraception and drug use. In 2016 he joined the Mount Sinai Program for the Protection of Human Subjects as an IRB analyst and transitioned back to clinical research in mid-2017 where Mr. Van Geem worked on pediatric epilepsy studies, including the Greenwich Pharmaceuticals trial that allowed cannibidiol (CBD) FDA approval for treating Lennox-Gastaut Syndrome, and ultimately helped get CBD rescheduled. In 2020, Mr. Van Geem moved to amyotrophic lateral sclerosis (ALS) research before taking on the role of Program Manager for the NeuroNEXT Program across the Mount Sinai Health System.